3SOF

  WOW, look at that volume!. More than half the outstanding shares have changed hands.

Lots of profit taking and lots of support.


uc.

People are so nervous trading stocks that they are taking every short term gain they have, even selling stocks with enormous potential like NVAX.

We've had great news today:

Novavax Completes ESTRASORB Partnership

The company will make a conference call tomorrow at 10am.

Just look at the huge volume on the stock, much higher now than before the breakout. I see today's action as profit taking, but also the first signs of the start of a Bird Flu bubble mania. I'm telling you, it will be hard to hold on, but this stock may run higher and faster than anyone can imagine at this point.

You see, there's no time. The bubble must develop from now until Christmas, because that's the Flu season.

Maybe the stock will correct some more, but I don't think it will go down much and by the end of the week we'll be seeing new highs on the whole Bird Flu group. Everyone will be rushing to get in before the weekend, when people will spend a lot of time talking, thinking, reading and listening to Bird Flu related news.

The case could unfortunately be a pandemic, but even if nothing happens, I see a global rush to pick up these stocks. Time will tell.

Maybe this will get it back on track.   

http://biz.yahoo.com/prnews/051018/phtu070.html?.v=1

Profit taking today!  Buy back tomorrow on dip/rebound.

Amazing 28.8 million shares today.  WOW

More institutional/money manager accumulation (none of them sold):

Profit taking today!  Buy back tomorrow on dip/rebound.

Amazing 28.8 million shares today.  WOW

More institutional/money manager accumulation (none of them sold):

More good news for NVAX:

http://biz.yahoo.com/prnews/051018/phtu070.html?.v=1

Novavax Completes ESTRASORB Partnership
Tuesday October 18, 5:31 pm ET

MALVERN, Pa., Oct. 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) announced today that it has entered into a definitive license and supply agreement on ESTRASORB® (estradiol topical emulsion) with Esprit Pharma, a private specialty pharmaceutical company based in East Brunswick, NJ. Under the License Agreement, Esprit Pharma will obtain exclusive rights to market ESTRASORB in North America. Novavax will continue to manufacture ESTRASORB in its state-of-the-art pharmaceutical plant in Philadelphia. Esprit will pay Novavax a minimum cash consideration of $12.5 million, $2.0 million which was paid today, $8.0 million payable by year-end 2005, and the remaining balance of $2.5 million payable at the first anniversary of the Agreement in October 2006. Novavax will also receive a royalty on all net sales of ESTRASORB. Additionally, Esprit is obligated to pay Novavax certain milestone payments based on specific pre-determined net sales levels of ESTRASORB. This transaction today allows Novavax to continue to realize potential ESTRASORB marketing partnerships with other companies in international markets around the world.

"We are delighted with our new partnership with Esprit and believe that ESTRASORB is in the right hands with the necessary resources to achieve its full potential in the marketplace," said Ray Hage, Senior Vice President and COO of Novavax. "John Spitznagel and his team at Esprit have a remarkable track record of success in launching new products and building pharmaceutical companies. An example is their most recent successful venture in ESP Pharma, which this management team built and sold to Protein Design Labs, Inc. for approximately $500 million. Under the new licensing deal structure announced today, Novavax shareholders will realize the benefits from the marketing success of ESTRASORB anticipated under Esprit management."

"We are very excited about adding ESTRASORB to our product portfolio," said John T. Spitznagel, Esprit's Chairman and CEO. "Novavax's unique micellar nanoparticle (MNP) technology platform delivers estrogen through the skin in a therapeutically effective and consumer friendly manner. The acquisition of ESTRASORB reflects our ongoing and growing commitment to women's healthcare. We view today's Licensing Agreement as the beginning of a longer-term relationship with the management team of Novavax. We intend to work with Novavax to explore further use of its technologies in expanding our product pipeline."

"This partnership is a watershed event for Novavax. It culminates our strategy of transitioning from a commercial business model and focusing on our core competency of product development," said Dr. Rahul Singhvi, President and CEO of Novavax, Inc. "This agreement further strengthens our balance sheet and puts us in a position to advance our promising pandemic (avian) flu vaccine program as well as several new product candidates utilizing our MNP technology into clinical development."

Conference call tomorrow morning:

http://biz.yahoo.com/prnews/051018/phtu075.html?.v=1

Novavax Announces Conference Call
Tuesday October 18, 6:01 pm ET

MALVERN, Pa., Oct. 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) a specialty biopharmaceutical company, today announced the Company will hold a conference call tomorrow morning at 10 am (EST) to discuss a significant transaction on the Company's primary product, ESTRASORB®. The call will be hosted by Mr. Gary C. Evans, Chairman of the Board, Dr. Rahul Singhvi, President and CEO, and Mr. Ray Hage, Senior Vice President and Chief Operating Officer to discuss the ESTRASORB Licensing Agreement announced today which will be followed by a question and answer session. Also participating on the call from Esprit Pharma will be Andrew J. Einhorn, EVP and Chief Financial Officer, and Lou Berardi, EVP of Business Development. The dial-in number for the conference call is 1 (800) 706-7748 pass code 36718556.

A live audio webcast of the conference call will be available through http://www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days starting on October 19th, 2005 at http://www.novavax.com. A replay of the conference call will also be available by telephone on October 19, 2005 through October 26, 2005. To access the replay, dial 1 (888) 286-8010 and enter pass code 37589208.

Conference call tomorrow morning:

http://biz.yahoo.com/prnews/051018/phtu075.html?.v=1

Novavax Announces Conference Call
Tuesday October 18, 6:01 pm ET

MALVERN, Pa., Oct. 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) a specialty biopharmaceutical company, today announced the Company will hold a conference call tomorrow morning at 10 am (EST) to discuss a significant transaction on the Company's primary product, ESTRASORB®. The call will be hosted by Mr. Gary C. Evans, Chairman of the Board, Dr. Rahul Singhvi, President and CEO, and Mr. Ray Hage, Senior Vice President and Chief Operating Officer to discuss the ESTRASORB Licensing Agreement announced today which will be followed by a question and answer session. Also participating on the call from Esprit Pharma will be Andrew J. Einhorn, EVP and Chief Financial Officer, and Lou Berardi, EVP of Business Development. The dial-in number for the conference call is 1 (800) 706-7748 pass code 36718556.

A live audio webcast of the conference call will be available through http://www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days starting on October 19th, 2005 at http://www.novavax.com. A replay of the conference call will also be available by telephone on October 19, 2005 through October 26, 2005. To access the replay, dial 1 (888) 286-8010 and enter pass code 37589208.

Quote from: LiveLife on October 18, 2005, 08:07:05 PM
More good news for NVAX:

http://biz.yahoo.com/prnews/051018/phtu070.html?.v=1

..... Esprit will pay Novavax a minimum cash consideration of $12.5 million, $2.0 million which was paid today, $8.0 million payable by year-end 2005, and the remaining balance of $2.5 million payable at the first anniversary of the Agreement in October 2006...."

Huge NEWS!!!  The stock closed up 11% in after hour trading at 3.26.  Tomorrow this thing is going to FLY!  And just to think this stock was trading at 0.80 back in August!!!

Good luck to all holding this one!

My theory on today's sell off:

After such a large gain, profit taking was anticipated.  There was a sectorwide sell off today this afternoon (Avian plays all had large gains) supplemented by the current "bearish" market conditions.  This further triggered the "nervous me-too" retail traders who may have bought today and saw their value drop and sold off.

Institutional/money managers bought all day long again with NO SELLING.

As long as accumulation by managers continue, I will hold, but take profit along the way 

If there was a sectorwide profit taking, then the sellers will return to buy back on dip.


Also, take a  look at all the events coming together:

-Avian news coverage 24/7
-New CEO with MIT/Patents
-Bush, UN, WHO pushing need for vaccine (summit and conference with CEOs)
-Need for millions of vaccine doses
-NVAX cell culturing systems with 2 month production time
-Threat of mutation requiring new vaccine production
-More spreading of Avian
-$12 million Joint Venture
-Conference call tomorrow morning
-Presentation by CEO at Bio Investor Forum tomorrow

I mean, just look at this sequence of events!!!

More joint venture agreements, more licenses, more threat, more vaccine, possible merger/buy out. You think the Institution/money managers are thinking the same thing? You bet!

Good trading!

My theory on today's sell off:

After such a large gain, profit taking was anticipated.  There was a sectorwide sell off today this afternoon (Avian plays all had large gains) supplemented by the current "bearish" market conditions.  This further triggered the "nervous me-too" retail traders who may have bought today and saw their value drop and sold off.

Institutional/money managers bought all day long again with NO SELLING.

As long as accumulation by managers continue, I will hold, but take profit along the way   

If there was a sectorwide profit taking, then the sellers will return to buy back on dip.


Also, take a  look at all the events coming together:

-Avian news coverage 24/7
-New CEO with MIT/Patents
-Bush, UN, WHO pushing need for vaccine (summit and conference with CEOs)
-Need for millions of vaccine doses
-NVAX cell culturing systems with 2 month production time
-Threat of mutation requiring new vaccine production
-More spreading of Avian
-$12 million Joint Venture
-Conference call tomorrow morning
-Presentation by CEO at Bio Investor Forum tomorrow

I mean, just look at this sequence of events!!!

More joint venture agreements, more licenses, more threat, more vaccine, possible merger/buy out. You think the Institution/money managers are thinking the same thing? You bet!

Good trading!

NEWS out:

Novavax Completes ESTRASORB Partnership
Tuesday October 18, 5:31 pm ET

MALVERN, Pa., Oct. 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) announced today that it has entered into a definitive license and supply agreement on ESTRASORB® (estradiol topical emulsion) with Esprit Pharma, a private specialty pharmaceutical company based in East Brunswick, NJ. Under the License Agreement, Esprit Pharma will obtain exclusive rights to market ESTRASORB in North America. Novavax will continue to manufacture ESTRASORB in its state-of-the-art pharmaceutical plant in Philadelphia. Esprit will pay Novavax a minimum cash consideration of $12.5 million, $2.0 million which was paid today, $8.0 million payable by year-end 2005, and the remaining balance of $2.5 million payable at the first anniversary of the Agreement in October 2006. Novavax will also receive a royalty on all net sales of ESTRASORB. Additionally, Esprit is obligated to pay Novavax certain milestone payments based on specific pre-determined net sales levels of ESTRASORB. This transaction today allows Novavax to continue to realize potential ESTRASORB marketing partnerships with other companies in international markets around the world.

ADVERTISEMENT
"We are delighted with our new partnership with Esprit and believe that ESTRASORB is in the right hands with the necessary resources to achieve its full potential in the marketplace," said Ray Hage, Senior Vice President and COO of Novavax. "John Spitznagel and his team at Esprit have a remarkable track record of success in launching new products and building pharmaceutical companies. An example is their most recent successful venture in ESP Pharma, which this management team built and sold to Protein Design Labs, Inc. for approximately $500 million. Under the new licensing deal structure announced today, Novavax shareholders will realize the benefits from the marketing success of ESTRASORB anticipated under Esprit management."

"We are very excited about adding ESTRASORB to our product portfolio," said John T. Spitznagel, Esprit's Chairman and CEO. "Novavax's unique micellar nanoparticle (MNP) technology platform delivers estrogen through the skin in a therapeutically effective and consumer friendly manner. The acquisition of ESTRASORB reflects our ongoing and growing commitment to women's healthcare. We view today's Licensing Agreement as the beginning of a longer-term relationship with the management team of Novavax. We intend to work with Novavax to explore further use of its technologies in expanding our product pipeline."

"This partnership is a watershed event for Novavax. It culminates our strategy of transitioning from a commercial business model and focusing on our core competency of product development," said Dr. Rahul Singhvi, President and CEO of Novavax, Inc. "This agreement further strengthens our balance sheet and puts us in a position to advance our promising pandemic (avian) flu vaccine program as well as several new product candidates utilizing our MNP technology into clinical development."

lalitha

Conference call highlights (mostly on Estrasorb.  Some Avian issues.  CEO to address Avian issues later today in San Francisco Bio Investor Forum):

- $12 million venture signed and done ($2 million payment made yesterday)
- Exclusive distribution of Estrasorb
- Have 3 solid financial firms backing NVAX
- Have 100 sales representatives in the field working with OB/GYN and health care services staff - this number will be "significantly" increased in the coming months to promote the products
- There are at least two other new products ready to launch
- Definite Avian virus play- nice 
- CEO on Avian vaccine response - NVAX has the large scale production process to produce the vaccine, once an effective vaccine is identified (customized vaccine for Avian)
- CEO believes that there is not an effective vaccine at the moment, but a customized vaccine for Avian is in the works, with NVAX having the process to mass produce, regardless of who develops the vaccine
- NVAX worked hard to find a large pharmaceutical to distribute Estrasorb, and King Pharmaceutical was a "mistake" and thus had a negative affect on NVAX.  Found new partner to market the product
- Finding from prescribing physicians that Estrasorb is effective and female patients are confirming the effectiveness of the product and coming back
- Two new products will be launched in 2 weeks
- The overall hormonal replacement therapy taken orally (3/4 of market) is declining.  Estrasorb uses transdermal (through skin) and transdermal delivery segment has been increasing
- NVAX will be spending more money on R&D for Avian virus (CEO will do more coverage at the Bio Investor Forum presentation)
- NVAX has contacts in the high-level government and this is important for NVAX to continue to work with the high-level government in regards to the government's response to the Avian pandemic threat and to secure CONTRACTS!!! - WOW, right from the CEO's mouth!!!

End of conference call.

WOW.

Good news for NVAX, can't wait for the Bio Investor Forum, but I gotta go to work.

I'll check the transcript of the presentation.

Good trading!

Conference call highlights (mostly on Estrasorb.  Some Avian issues.  CEO to address Avian issues later today in San Francisco Bio Investor Forum):

- $12 million venture signed and done ($2 million payment made yesterday)
- Exclusive distribution of Estrasorb
- Have 3 solid financial firms backing NVAX
- Have 100 sales representatives in the field working with OB/GYN and health care services staff - this number will be "significantly" increased in the coming months to promote the products
- There are at least two other new products ready to launch
- Definite Avian virus play- nice   
- CEO on Avian vaccine response - NVAX has the large scale production process to produce the vaccine, once an effective vaccine is identified (customized vaccine for Avian)
- CEO believes that there is not an effective vaccine at the moment, but a customized vaccine for Avian is in the works, with NVAX having the process to mass produce, regardless of who develops the vaccine
- NVAX worked hard to find a large pharmaceutical to distribute Estrasorb, and King Pharmaceutical was a "mistake" and thus had a negative affect on NVAX.  Found new partner to market the product
- Finding from prescribing physicians that Estrasorb is effective and female patients are confirming the effectiveness of the product and coming back
- Two new products will be launched in 2 weeks
- The overall hormonal replacement therapy taken orally (3/4 of market) is declining.  Estrasorb uses transdermal (through skin) and transdermal delivery segment has been increasing
- NVAX will be spending more money on R&D for Avian virus (CEO will do more coverage at the Bio Investor Forum presentation)
- NVAX has contacts in the high-level government and this is important for NVAX to continue to work with the high-level government in regards to the government's response to the Avian pandemic threat and to secure CONTRACTS!!! - WOW, right from the CEO's mouth!!!

End of conference call.

WOW.

Good news for NVAX, can't wait for the Bio Investor Forum, but I gotta go to work.

I'll check the transcript of the presentation.

Good trading!

http://www.genengnews.com/news/bnitem.aspx?name=1082684XSL_NEWSML_TO_NEWSML_WEB.xml

Esprit Pharma Acquires Exclusive North American Rights to ESTRASORB(R) Topical Emulsion; Sees Growing Pre-Eminence in Women's Healthcare

10/18/2005 6:18:00 PM EST

Esprit Pharma, Inc. today announced that it acquired exclusive North American rights to ESTRASORB(R) (estradiol topical emulsion) from Novavax, Inc. (NASDAQ:NVAX). A topical emulsion form of the naturally occurring hormone 17beta-estradiol, ESTRASORB is the first prescription topical emulsion for estrogen therapy.

Applied once daily to the legs, ESTRASORB is approved for the treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause. The product utilizes Novavax's patented and proprietary micellar nanoparticle drug-delivery platform. This technology involves the application of a cosmetic like, moisturizing emulsion to deliver a therapeutic dose of 17beta-estradiol into the bloodstream when applied to the skin.

"We are very excited about adding ESTRASORB to our product portfolio," said John T. Spitznagel, Esprit's Chairman & CEO. "In addition to the product's unique technology platform which delivers estrogen therapy through the skin, thus bypassing the liver, the acquisition of ESTRASORB reflects our ongoing and growing commitment to our women's healthcare products. The licensing of ESTRASORB is the beginning of a longer-term strategic relationship with Novavax. We expect to work with Novavax to expand our product pipeline," continued Mr. Spitznagel.

"Together with our recently acquired PROQUIN(R) XR and PROSED(R) product lines, ESTRASORB strengthens our pre-eminence in the area of women's healthcare and offers substantial opportunities to realize benefits associated with product synergies," noted Mr. Spitznagel. He concluded saying, "Esprit is also in advanced discussions to acquire additional products in this specialty."

Commenting on today's announcement, Greg Stokes, President & COO of Esprit, stated, "ESTRASORB was approved for sale in late 2003 and launched by Novavax in mid 2004. Esprit will now re-launch and begin promoting ESTRASORB, taking advantage of our sales force and enhanced presence in women's healthcare."

Mr. Stokes further noted, "The product will compete in the non-systemic segment of the U.S. market for hormone replacement therapies (HRT) which is the only growing segment in the $1.5 billion U.S. HRT market. Moreover, research indicates that ESTRASORB is widely accepted by prescribers and patients due mainly to its transdermal route of administration."

"Given the product's delivery characteristics, plus the focused strength of our sales and marketing staff, backed by Esprit's dedication to medical education, we expect to realize substantial long-term growth in sales of ESTRASORB," concluded Mr. Stokes.

Financial terms of today's announced transaction were not disclosed.

About Esprit Pharma

Esprit Pharma is a niche oriented, forward thinking pharmaceutical company committed to improving patient outcomes and well-being within the Genito-urinary and women's health care fields. Led by a highly experienced management team, Esprit focuses on serving the unique needs of physicians by identifying opportunities and selectively acquiring and maximizing the potential of approved and late-stage development medicines and providing support through internal expertise and a dedication to medical education. A privately held company, Esprit has investment support from the leading healthcare venture capital and private equity firms of Domain Associates, LLC (http://www.domainvc.com), New Enterprise Associates (http://www.nea.com) and Apax Partners, Inc. (http://www.apax.com). For additional information visit the Company's Internet site at www.EspritPharma.com.